196 related articles for article (PubMed ID: 28737239)
1. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
Osuga Y; Watanabe M; Hagino A
J Obstet Gynaecol Res; 2017 Sep; 43(9):1441-1448. PubMed ID: 28737239
[TBL] [Abstract][Full Text] [Related]
2. Long-term dienogest administration in patients with symptomatic adenomyosis.
Neriishi K; Hirata T; Fukuda S; Izumi G; Nakazawa A; Yamamoto N; Harada M; Hirota Y; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
J Obstet Gynaecol Res; 2018 Aug; 44(8):1439-1444. PubMed ID: 29845696
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Fujimoto-Okabe H; Hagino A
Fertil Steril; 2017 Oct; 108(4):673-678. PubMed ID: 28911934
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
Hirata T; Izumi G; Takamura M; Saito A; Nakazawa A; Harada M; Hirota Y; Koga K; Fujii T; Osuga Y
Gynecol Endocrinol; 2014 Oct; 30(10):726-9. PubMed ID: 24905725
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of dienogest for the treatment of primary and secondary dysmenorrhea.
Osuga Y; Hayashi K; Kanda S
J Obstet Gynaecol Res; 2020 Apr; 46(4):606-617. PubMed ID: 32050307
[TBL] [Abstract][Full Text] [Related]
6. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
Ota K; Takahashi T; Shiraishi S; Mizunuma H
J Obstet Gynaecol Res; 2018 Sep; 44(9):1787-1792. PubMed ID: 29998482
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
8. Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Hayashi K; Kanda S
Fertil Steril; 2020 Jan; 113(1):167-175. PubMed ID: 31727415
[TBL] [Abstract][Full Text] [Related]
9. Long-term use of dienogest for the treatment of endometriosis.
Momoeda M; Harada T; Terakawa N; Aso T; Fukunaga M; Hagino H; Taketani Y
J Obstet Gynaecol Res; 2009 Dec; 35(6):1069-76. PubMed ID: 20025633
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, placebo-controlled, double-blind, comparative study of dienogest at 1 mg/day in patients with primary and secondary dysmenorrhea.
Osuga Y; Hayashi K; Kanda S
Fertil Steril; 2020 Mar; 113(3):627-635.e1. PubMed ID: 32192595
[TBL] [Abstract][Full Text] [Related]
12. Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
Xue J; Li L; Li F; Li N; Li T; Li C
J Reprod Immunol; 2020 Feb; 137():103079. PubMed ID: 31927399
[TBL] [Abstract][Full Text] [Related]
13. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
14. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma.
Lee SR; Yi KW; Song JY; Seo SK; Lee DY; Cho S; Kim SH
Reprod Sci; 2018 Mar; 25(3):341-346. PubMed ID: 29161960
[TBL] [Abstract][Full Text] [Related]
16. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
Guo W; Lin Y; Hu S; Shen Y
Clin Ther; 2023 Oct; 45(10):973-976. PubMed ID: 37599165
[TBL] [Abstract][Full Text] [Related]
17. Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Matsubara S; Kawaguchi R; Akinishi M; Nagayasu M; Iwai K; Niiro E; Yamada Y; Tanase Y; Kobayashi H
Sci Rep; 2019 Nov; 9(1):17654. PubMed ID: 31776404
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
Fawzy M; Mesbah Y
Arch Gynecol Obstet; 2015 Dec; 292(6):1267-71. PubMed ID: 25990480
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments.
Kobayashi H
Gynecol Obstet Invest; 2023; 88(2):71-80. PubMed ID: 36682346
[TBL] [Abstract][Full Text] [Related]
20. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]